HIGHLIGHTS
- who: Stephen L. Chan from the State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong, China have published the research work: A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors, in the Journal: (JOURNAL)
- what: This study was designed to determine the recommended phase 2 dose (RP2D) characterize PK/PD and evaluate the safety and efficacy of FGF401 alone and combined with the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.